Adding a cholesterol-lowering medicine to lorlatinib for high cholesterol
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether combining a new cholesterol-lowering drug (a PCSK9 inhibitor) with your current lorlatinib can help manage the high cholesterol that lorlatinib may cause, without affecting its anti-cancer effect. It aims to protect your heart health while you continue effective lung cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your lung cancer must be advanced (stage IIIB, IIIC, or IV) and not removable by surgery.
- You must have a specific gene change called ALK fusion, confirmed by a test.
- After taking lorlatinib, you developed high cholesterol (mild to moderate).
- Your fasting triglyceride level (a type of fat in your blood) must be below 5.6 mmol/L at screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different ways to manage high cholesterol (hyperlipidemia) that happens as a side effect of the drug lorlatinib, which is used to treat ALK-positive lung cancer. Participants will receive additional cholesterol-lowering medicines or strategies, and the study aims to find the best way to keep cholesterol in check while continuing effective cancer treatment.
This study looks at how the drug Lorlatinib affects cholesterol levels in people with ALK-positive non-small cell lung cancer. It aims to understand and manage these side effects better.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
This trial tests a combination of two targeted therapies (lorlatinib and sacituzumab tirumotecan) as first treatment for advanced non-small cell lung cancer with an ALK gene change. The goal is to see if the combination works better than current treatments and to use a simple blood test to guide therapy.
Hear when a new ALK Fusion-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.